Loading...
•
Mar 31, 2021
Mersana Q1 2021 Earnings Report
Mersana Therapeutics reported financial results for the first quarter ended March 31, 2021 and provided a business update.
Key Takeaways
Mersana Therapeutics announced the initiation of UPLIFT, a single-arm registrational strategy for evaluating UpRi in platinum-resistant ovarian cancer. The company ended the first quarter of 2021 with $228.4 million in cash and cash equivalents.
Initiated UPLIFT single-arm registration strategy for evaluation of UpRi in platinum-resistant ovarian cancer.
UpRi has demonstrated promising activity and a differentiated tolerability profile.
Remain on track to initiate the UPGRADE umbrella combination study in the third quarter of 2021.
Ended first quarter of 2021 with $228.4 million in cash.
Forward Guidance
The Company expects that its available funds will be sufficient to support its operating plan commitments for approximately two years.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...